Dr. ANM Nazmul Khan joined the staff of Roswell Park Cancer Institute (RPCI) in 2011 as a Scientist in the Division of Infectious Disease, Department of Medicine. Prior to joining the Department of Medicine he completed post-doctoral training in the Department of Immunology and Molecular Medicine at RPCI.
Dr. Khan earned his medical degree (MBBS) from Dhaka Medical College, Bangladesh, and worked as a clinical physician in different hospitals in Bangladesh and Botswana until 1998. He earned his PhD in Immunology from the State University of New York at Buffalo in 2005.
Dr. Khan is a member of the American Association of Immunologists and the American Association for Cancer Research. He has authored or co-authored more than 25 journal publications, review articles and abstracts.
Dr. Khan’s research interests include the role of innate immune cells (e.g., neutrophils, platelets, macrophages) and damage associated molecular patterns (DAMPs) in tumor growth; overcoming myeloid cell-derived immunosuppression to enhance cancer vaccine efficacy; the mechanisms involved in modulating functional effects of innate immune cells against pathogens or tumor; development of immune-based therapy and prognostic biomarkers for ovarian cancer.
Kolomeyevskaya N, Eng KH, Khan AN, Grzankowski KS, Singel KL, Moysich K, Segal BH (2015) Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol. First published online May 20, 2015
Khan AN*, Kolomeyevskaya N*, Singel KL*, Grimm MJ, Moysich KB, Daudi S, Lele S, Ylagan L, Webster GA, Abrams SI, Odunsi K and Segal BH (2015) Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in epithelial ovarian cancer. Oncotarget, 6(13):11310-26.
Paulus A, Masood A, Miller KC, Khan AN, Akhter D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K and Chanan-Khan A (2014) The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Br J Haematol, 165(1):78-88
Godoy HE*, Khan AN*, Vethanayagam RR, Grimm MJ, Singel KL, Kolomeyevskaya N, Sexton KJ, Parameswaran A , Abrams SI, Odunsi K, Segal BH (2013) Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice. PLoS One, 8(7):e69631
Chitta KS, Khan AN, Ersing N, Swaika A, Masood A, Paulus A, Qadeer A, Advani P, Sher T, Miller KC, Lee K, Chanan-Khan AA (2013) Neem leaf extract induces cell death by apoptosis and autophagy in B-Chronic Lymphocytic Leukemia cells. Leuk Lymphoma. May 31 e-print
Grimm MJ, Vethanayagam RR, Almyroudis NG, Dennis CG, Khan AN, D'Auria AC et al (2013) Monocyte- and macrophage-targeted NADPH oxidase mediates antifungal host defense and regulation of acute inflammation in mice. J Immunol, 190(8):4175-8
Banik D*, Khan AN*, Walseng E, Segal BH, Abrams SI (2012) Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity. PLoS One, 7(9):e45422
Segal BH, Grimm MJ, Khan AN, Han W, Blackwell TS (2012) Regulation of innate immunity by NADPH oxidase. Free Radic Biol Med, 53(1):72-80
Khan AN, Tomasi TB (2008) Histone deacetylase regulation of immune gene expression in tumor cells. Immunologic Research, 40(2):164-78
Khan AN, Gregorie C, Tomasi TB (2008) Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunology Immunotherapy, 57(5):647-54
Khan AN, Magner WJ, Tomasi TB (2007) An epigenetic vaccine model active in the prevention and treatment of melanoma. J Translational Medicine, 5:64.
Tomasi TB, Magner WJ and Khan AN (2006) Epigenetic regulation of immune escape genes in cancer. Cancer Immunology Immunotherapy, 55: 1159 – 1184
Altieri SA, Khan AN, Tomasi TB (2004) Exosomes from plasmacytoma cells as a tumor vaccine. Journal of Immunotherapy 27(4): 282 – 288
Khan AN, Magner WJ, Tomasi TB (2004) An epigenetically altered tumor cell vaccine. Cancer Immunology Immunotherapy 53(8): 748 – 754.